Recurrent somatic inactivating PTPRJ mutations and key dysregulated pathways identified in canine melanoma by integrated genomic analysis. Hendricks W, Zismann V, Legendre C, Tembe W, Kiefer J, Button B, Bittner M, Liang W, Stark M, Poorman K, LoRusso P, Berry D, Ruhe A, Froman R, Duesbury N, Neff M, Hewitt S, Huentelman M, Breen M, Craig D, Hayward N, Khanna C, Davis B, Sekulic A, Trent J. Nature Communications. Invited manuscript in preparation.
Dual loss of the SWI/SNF complex ATPase SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcemic type. Karnezis A, Wang Y, Ramos P, Hendricks W, Oliva E, D’Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Fabiana A, Da Silva L, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG. The Journal of Pathology. In Press.
Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Ramos P, Karnezis A, Hendricks W,
Wang Y, Tembe W, Zismann V, Legendre C, Liang W, Russell M, Craig D, Farley J, Monk B, Anthony S, Sekulic A, Cunliffe H, Huntsman D, Trent JM. Rare Diseases. 2014, Nov; 2.
Formulating the magic bullet: barriers to clinical translation of nanoparticle cancer gene therapy. Hendricks W, Yang J, Sur S & Zhou S. Nanomedicine. 2014, June; 9:1121-1124.